Search

Sarepta Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

19.97 -3.39

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

19.59

Max

20.11

Galvenie mērījumi

By Trading Economics

Ienākumi

-4.9M

326M

Pārdošana

-330M

401M

P/E

Sektora vidējais

42.919

56.432

EPS

0.42

Peļņas marža

81.263

Darbinieki

835

EBITDA

-345M

30M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+10.82% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 2. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

533M

2.2B

Iepriekšējā atvēršanas cena

23.36

Iepriekšējā slēgšanas cena

19.97

Ziņu noskaņojums

By Acuity

40%

60%

70 / 339 Rangs Healthcare

Sarepta Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 18. sept. 19:51 UTC

Sarepta Therapeutics Inc shares fell sharply, continuing a significant decline since Thursday and trading well below its 20-day moving average.

2026. g. 17. sept. 20:02 UTC

Sarepta Therapeutics Inc shares are sharply higher, showing notable volatility and remaining well above the 20-day moving average since Wednesday's close.

2026. g. 16. sept. 23:06 UTC

Sarepta Therapeutics Inc. is trading modestly higher in after-market hours following a notable early spike, despite closing lower in three consecutive sessions.

2026. g. 14. sept. 20:07 UTC

Sarepta Therapeutics shares are higher, reflecting broader market strength despite pulling back from an earlier session peak. No specific news was identified for the movement.

2026. g. 12. sept. 00:01 UTC

Sarepta Therapeutics Inc shares are lower in after-market trading, following a decline earlier in the session amid broader inflation concerns ahead of a Federal Reserve meeting.

2026. g. 11. sept. 23:31 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours with no specific news to explain the decline amid broader market speculation on Federal Reserve rate hikes.

2026. g. 10. sept. 20:03 UTC

Sarepta Therapeutics Inc shares are lower today, continuing a decline since Wednesday. No specific news was identified to explain the drop.

2026. g. 9. sept. 23:21 UTC

Sarepta Therapeutics shares are lower in after-market hours, following a broader market trend amid rising U.S. Treasury yields impacting borrowing costs.

2026. g. 8. sept. 23:21 UTC

Social Media

Sarepta Therapeutics is higher in after-market trading amid social media interest in its $2.1 billion market cap and revenue projections for fiscal year 2026.

2026. g. 4. sept. 23:25 UTC

Sarepta Therapeutics Inc. shares declined after-market, reflecting unusual weakness since Friday's close, despite remaining above the 20-day moving average.

2026. g. 3. sept. 23:36 UTC

Sarepta Therapeutics Inc. shares traded roughly flat after market hours, while major indices gained amid easing interest rate concerns.

2026. g. 2. sept. 20:02 UTC

Social Media

Sarepta Therapeutics shares are higher as investor interest grows ahead of clinical data for treatments targeting muscular dystrophy, despite a pullback from session highs.

2026. g. 1. sept. 20:09 UTC

Sarepta Therapeutics Inc shares are higher today, supported by gains in the Biotechnology sub-sector. The stock remains above its 20-day moving average.

2026. g. 31. aug. 20:07 UTC

Sarepta Therapeutics shares are higher amid broader market concerns over inflation, with no specific company news identified to explain the movement.

2026. g. 28. aug. 19:51 UTC

News

Sarepta Therapeutics reported a 34% revenue decline to $401.3 million for Q2 2026, as execution risks weigh on shares during the current session.

2026. g. 27. aug. 23:02 UTC

Sarepta Therapeutics shares declined in after-market trading amid a broader market pullback, despite earlier gains during the session. No specific news was identified.

2026. g. 26. aug. 20:08 UTC

Sarepta Therapeutics Inc shares are higher today amid broader market gains, despite no specific company news identified. Recent inflation data may be influencing market trends.

2026. g. 25. aug. 19:26 UTC

Sarepta Therapeutics Inc. shares are higher today amid notable volatility, despite no specific news to explain the movement. Broader market conditions support higher valuations.

2026. g. 24. aug. 20:06 UTC

News

Sarepta Therapeutics shares decline amid investigation into potential fiduciary breaches and safety concerns regarding its gene therapy, Elevidys.

2026. g. 21. aug. 19:26 UTC

Sarepta Therapeutics Inc is trading lower today, with no specific news identified for the decline. Broader market trends show a rebound in U.S. stocks.

2026. g. 20. aug. 23:56 UTC

Sarepta Therapeutics Inc. shares traded roughly flat in after-market hours, remaining above their 20-day moving average and near the upper end of their one-month range.

2026. g. 19. aug. 23:11 UTC

Sarepta Therapeutics shares are lower in after-market hours amid a broader decline in the Biotechnology sub-sector, showing unusual volatility during the session.

2026. g. 18. aug. 23:11 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours, retracing gains amid broader market weakness linked to rising sovereign bond yields and inflation concerns.

2026. g. 17. aug. 19:36 UTC

Sarepta Therapeutics Inc shares are higher, continuing their advance since Friday's close and trading above the 20-day moving average. No specific news was identified.

2026. g. 14. aug. 19:36 UTC

Sarepta Therapeutics shares are lower today amid broader market sentiment following a reported decline in retail sales for July. No specific company news was identified.

2026. g. 13. aug. 19:36 UTC

Sarepta Therapeutics shares are trading roughly flat, with no specific news identified. The price remains significantly above the 20-day moving average.

2026. g. 12. aug. 23:51 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours, continuing a decline since Wednesday's close, with no specific news identified to explain the drop.

2026. g. 11. aug. 23:51 UTC

Sarepta Therapeutics Inc shares are lower in after-market trading. No specific news was identified to explain the movement amid broader market focus on inflation data.

2026. g. 10. aug. 23:52 UTC

Sarepta Therapeutics shares are lower in after-market hours, with no specific news identified for the decline amid broader market sentiment influenced by labor report data.

2026. g. 7. aug. 19:36 UTC

News

Sarepta Therapeutics reports Q2 2026 revenue of $401.3 million, down from $611.1 million a year earlier, with shares trading lower during the session.

Salīdzinājums

Cenas izmaiņa

Sarepta Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

10.82% augšup

Prognoze 12 mēnešiem

Vidējais 22.286 USD  10.82%

Augstākais 38 USD

Zemākais 5 USD

Pamatojoties uz 16 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Sarepta Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

16 ratings

4

Pirkt

8

Turēt

4

Pārdot

Noskaņojums

By Acuity

70 / 339 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.